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Abstract
Despite intense research and clinical efforts, patients affected by advanced colorectal cancer (CRC) have still a poor
prognosis. The discovery of colorectal (CR) cancer stem cell (CSC) as the cell compartment responsible for tumor initiation
and propagation may provide new opportunities for the development of new therapeutic strategies. Given the reduced
sensitivity of CR-CSCs to chemotherapy and the ability of bone morphogenetic proteins (BMP) to promote colonic stem cell
differentiation, we aimed to investigate whether an enhanced variant of BMP7 (BMP7v) could sensitize to chemotherapy-
resistant CRC cells and tumors. Thirty-five primary human cultures enriched in CR-CSCs, including four from
chemoresistant metastatic lesions, were used for in vitro studies and to generate CR-CSC-based mouse avatars to evaluate
tumor growth and progression upon treatment with BMP7v alone or in combination with standard therapy or PI3K
inhibitors. BMP7v treatment promotes CR-CSC differentiation and recapitulates the cell differentiation-related gene
expression profile by suppressing Wnt pathway activity and reducing mesenchymal traits and survival of CR-CSCs.
Moreover, in CR-CSC-based mouse avatars, BMP7v exerts an antiangiogenic effect and sensitizes tumor cells to standard
chemotherapy regardless of the mutational, MSI, and CMS profiles. Of note, tumor harboring PIK3CA mutations were
affected to a lower extent by the combination of BMP7v and chemotherapy. However, the addition of a PI3K inhibitor to the
BMP7v-based combination potentiates PIK3CA-mutant tumor drug response and reduces the metastatic lesion size. These
data suggest that BMP7v treatment may represent a useful antiangiogenic and prodifferentiation agent, which renders CSCs
sensitive to both standard and targeted therapies.
Introduction
Advanced colorectal cancer (CRC) is still a major challenge
for clinical oncologists, being among the top causes of
cancer-related death worldwide [1]. Cancer stem cells
These authors contributed equally: Ruggero De Maria, Giorgio Stassi




1 Department of Surgical, Oncological and Stomatological Sciences
(DICHIRONS), University of Palermo, 90127 Palermo, Italy
2 Department of Oncology and Molecular Medicine, Istituto
Superiore di Sanità, Rome, Italy
3 Istituto di Patologia Generale, Università Cattolica del Sacro
Cuore, 00168 Rome, Italy
4 Fondazione Policlinico Universitario A. Gemelli—I.R.C.C.S.,
00168 Rome, Italy
5 Department of Health Promotion Sciences, Internal Medicine and
Medical Specialties (PROMISE), University of Palermo, 90127
Palermo, Italy
6 Pathology Unit, Ospedali Riuniti Villa Sofia-Cervello,
Palermo, Italy
7 Lilly Research Laboratories, Lilly Corporate Center,
Indianapolis, IN 46285, USA
Supplementary information The online version of this article (https://
doi.org/10.1038/s41388-019-1047-4) contains supplementary















(CSCs) are key players in tumor initiation and development
of metastasis [2, 3]. In recent years, many studies inves-
tigating the biological behavior of CSCs inspired the
design of innovative therapeutic strategies for CRC.
Genetic and epigenetic changes, overexpression of anti-
apoptotic proteins, and enhanced DNA repair machinery
define the common traits of CSCs [4, 5]. The acquisition
of an epithelial–mesenchymal transition (EMT) pheno-
type confers to CSCs the ability to invade and metastasize
[6]. Among the most studied CSC markers, CD133 has
been reported to identify CR-CSCs [7]. More recently, we
determined that a splicing variant of CD44, CD44v6, is a
functional marker expressed in CR-CSCs able to migrate
and engraft at distant sites [8]. In line with the enhanced
Wnt signaling observed in CR CD44v6+ cells, β-catenin
activation induces CD44v6 expression in CR-CSCs. This
pathway is sustained by the activation of the PI3K/AKT
pathway, which promotes β-catenin activation through the
inhibition of GSK3β, a key component of its destruction
complex [8]. According to the multistep model, the pro-
gressive acquisition of mutations in proto-oncogenes or
tumor suppressor genes defines specific stages of CRC
[9]. Aberrant alterations of principal components of
pathways involved in intestinal stem cell self-renewal
endorse the disruption of intestinal niche equilibrium [10].
In addition to Wnt, Notch, and Sonic hedgehog pathways,
bone morphogenetic proteins (BMPs) finely regulate the
intestinal niche homeostasis balancing self-renewal and
differentiation [11, 12]. BMPs are members of the TGF-β
superfamily and regulate many fundamental biological
processes during development. BMPs bind both type I and
type II receptors (BMPR1A, BMPR1B, and BMPR2) to
achieve a variety of cellular functions [13]. The activation
of this pathway promotes the phosphorylation of SMAD1,
5, and 8 that in association with SMAD4 regulates the
expression of genes involved in the differentiation process
[14, 15]. BMP antagonists (gremlin and noggin) tightly
modulate BMPs activity [16]. In healthy colon mucosa,
the expression of BMPs and their antagonists is polarized.
BMPs are mainly located at the top, while BMP antago-
nists at the base of colon crypt [17]. Alterations of BMP
pathways can imbalance the homeostasis of the intestinal
stem cell niche, thus favoring the development and pro-
gression of CRC. Indeed, the loss of BMPR2 and SMAD4
expression has been reported in sporadic CRC, whereas
germline mutations of BMPR1 and SMAD4 genes have
been demonstrated to enhance the susceptibility to
develop juvenile polyposis, supporting that TGF-β sig-
naling inactivation plays a key role in CRC development
[18–22]. In intestinal stem cells, BMP signaling coun-
teracts the Wnt pathway activity by impairing the nuclear
accumulation of β-catenin through a PTEN-dependent
AKT inhibition [23]. This antagonistic activity of BMP
signaling against stem cells and Wnt pathway seems
preserved in the cancer counterpart as indicated by the
ability of BMP4 to promote differentiation and apoptosis
of CR-CSCs [24].
BMP expression varies across tumor subtypes [25].
BMP7 is widely expressed in many tumors including
breast, prostate, and colon cancer, and it is implicated in
the regulation of cell proliferation [26–28]. However, its
functional association with tumorigenicity and metastasis
formation is still poorly understood. Recently, a human
variant of BMP7 with enhanced stability and solubility
(BMP7v) has been developed, by introducing mutations
into the N terminus of BMP7 prodomain [29]. In glio-
blastoma stem-like cells, BMP7v impairs their pro-
liferation and invasive capability by inducing
differentiation [30] and significantly decreases angio-
genesis. BMP7v, unlike BMP7, is not recognized by
most of the BMP endogenous antagonists, such as nog-
gin, gremlin, chordin, and chordin-like 2, due to reduced
binding [31]. Disease progression in CRC is mostly due
to the emergence of chemoresistant CSCs after ther-
apeutic interventions [32]. Different mechanisms and
biomarkers have been proposed so far to study and pre-
dict chemoresistance. Both microsatellite instability
(MSI) and consensus molecular subtype (CMS) profiles
correlate with the chemotherapy response in CRC. Spe-
cifically, MSI CRCs have been correlated with a better
prognosis [33] but also with a lack of benefit from oxa-
liplatin (oxa) plus 5-fluorouracil (5-FU) therapy [34, 35].
CMS2 CRC is as the subset that most benefits from the
chemotherapy, while the CMS4 results resistant to con-
ventional therapy [36, 37]. We demonstrated that the
activation of the PI3K/AKT pathway is essential for
preserving the stem cell status in CRC CD44v6+ cells
[8]. PI3K activation results in the onset of alternative
signaling pathways, including Wnt-β-catenin axis acti-
vation that promotes CR-CSC survival, invasion, and
development of metastases [38]. Using the BMP7v, here
we have studied the possibility of targeting chemoresis-
tant CRC through the induction of CSC differentiation.
We provide evidence supporting the use of BMP7v in
combination with chemotherapeutic compounds and/or
PI3K inhibitors for CRC treatment.
Results
BMP7 is highly expressed in low-grade CRC patients
In accordance with the current literature, we found BMP7
abundantly expressed in CRC tissues, compared with
peritumoral mucosa (Fig. 1a). BMP7 expression was
limited to the apical part and absent in the LGR5+ stem
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cells located at the very base of the cancer gland (Fig. 1a,
left panel). Analysis of a cohort of 158 CRC patients
showed a significant correlation between medium/high
BMP7 expression and the low-grade (I-II) tumors, which
was confirmed by the analysis of a cohort of CRC in R2
database (Fig. 1b, c and Supplementary Fig. 1a). Inter-
estingly, BMP7 was found highly expressed in both colon
adenoma and adenocarcinoma, suggesting this phenom-
enon as an early event in cancer (Fig. 1d). In line with the
expression of BMP7 in the differentiated part of the colon
gland, BMP7 was remarkably expressed in sphere-derived
adherent cells (SDACs), while it was present in few cells
across CRC spheres, which are enriched in stem-like cells
(Fig. 1e). Moreover, we found that CD133- cells showed a
higher percentage of BMP7-expressing cells as compared
with the CD133+ compartment (Fig. 1f and Supplemen-
tary Fig. 1b, c). Interestingly, CD44v6+ cells lacked
BMP7 expression, which was conversely confined to the
CD44v6- cell compartment (Fig. 1g and Supplementary
Fig. 1d, e). In accordance with the immunofluorescence
studies, flow cytometry analysis showed that BMP7 is
expressed in CD133−/CD44v6− cells and in a fraction of
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CD133+ cell compartment, whereas it is nearly undetect-
able in enriched CD44v6+/CD133+ stem-like cells (Fig. 1h).
These data demonstrate that BMP7 is predominantly
expressed in differentiated CRC cell population, particularly
in low-grade CRCs.
BMP7v affects CD44v6 expression in CR-CSCs
In order to define the potential of BMP7 as a prodiffer-
entiation agent, we next evaluated whether the BMP sig-
naling pathway components were conserved in a CRC
model. We observed that type I and type II BMP receptors
are expressed in both CD44v6+ and CD44v6− fraction with
more pronounced expression levels of BMPR2 in the
CD44v6− counterpart (Supplementary Fig. 2a, b). In order
to investigate the effects of BMP7 on CR-CSCs, we used a
modified BMP7 with enhanced stability and solubility
(BMP7v) as previously described [30]. The dose con-
centration of 100 ng/ml of BMP7v corresponded to the
IC50 and was also preferred for the in vitro ability to inhibit
the colony forming capacity of CR-CSCs even in the pre-
sence of high doses of BMP antagonists, gremlin, and
noggin (Supplementary Fig. 2c, d). CD44v6+ cells exposed
to BMP7v up to 21 days displayed a gradual morphological
differentiation (Fig. 2a), paralleled by the acquisition of
CK20 expression (Fig. 2b). In accordance, BMP7v sig-
nificantly reduced the percentage of cells expressing the
CD133/CD44v6 CSC markers and increased the number of
CDX2+ cells within CRC spheres (Fig. 2c, d and Supple-
mentary Fig. 2e, f). In a cohort of CRC patients, expression
levels of CDX2 are inversely correlated with tumor grading
(Supplementary Fig. 2g).
Interestingly, flow cytometry analysis of primary CRC
sphere cells transduced with a β-catenin/TOP-dGFP
reporter lentiviral vector showed that exposure to BMP7v
was able to progressively decrease β-catenin activity and
CD44v6 expression (Fig. 2e and Supplementary Fig. 2h).
Moreover, BMP7v treatment caused the reduction of
β-catenin activity and differentiation of CRC organoid,
which was highlighted by lumen formation and cell
polarization (Fig. 2f and Supplementary Fig. 2i). In the
presence of BMP7v, CD44v6+ CRC sphere cells acquired
E-cadherin expression, displayed loss of vimentin and
reduction of nuclear β-catenin (Fig. 2g). A large cohort of
CRC patients showed a positive correlation between the
expression levels of BMP7 and E-cadherin (CDH1) (Sup-
plementary Fig. 3a). In agreement, xenograft tumors gen-
erated by the injection of CR-CSCs (CSC# 1, 8, and 25),
displayed a major number of cells expressing E-cadherin
after BMP7v treatment (Supplementary Fig. 3b). Accord-
ingly, the in vitro invasive capacity of CD44v6+ CR-CSCs
was significantly impaired following treatment with BMP7v
(Fig. 2h). Following 96 h of treatment, CD44v6+ fraction
exhibited a more pronounced sensitivity to BMP7v-induced
cell death than CD44v6− cells (Fig. 2i). Although BMP7v
treatment did not significantly affect G0/G1 to G2/M phase
transition, it enhanced to a small extent the sub-G0 phase in
CD44v6+ CR-CSCs (Fig. 2j and Supplementary Fig. 3c). In
line with the induction of cell death, BMP7v treatment
induced activation of both PARP and Caspase-3 and a
downregulation of Bcl-2 and Bcl-xL in CD44v6+ cells (Fig. 2k
and Supplementary Fig. 3d, e). These data indicate that
BMP7v selectively targets the CD44v6+ CSC compartment
by counteracting its Wnt pathway activity and antiapoptotic
machinery.
BMP7v hampers the self-renewal capacity of CR-
CSCs
We have already reported that BMP7v activity is resistant
to the majority of BMP antagonists, such as noggin and
chordin [31]. Given that only some cancers express high
levels of gremlin and noggin [39, 40] we sought to
investigate their inhibitory effects on both BMP4 and
BMP7v. Although BMP4 was not able to accomplish its
function in the presence of gremlin and noggin, BMP7v
Fig. 1 BMP7 is confined to differentiated CRC cells. a Immuno-
fluorescence analysis of BMP7 (green color) and LGR5 (red color) on
peritumoral mucosa and colon cancer paraffin-embedded tissues per-
formed on CSC#8. One representative tumor from twenty different
tumors examined is shown. Nuclei were counterstained by Toto-3
(blue color). White arrowheads indicate LGR5+ cells at the base of
colon crypt. The scale bar represents 100 µm. b Immunohistochemical
analysis of BMP7 on CRC TMAs in lack, low, medium, and high
staining intensity (red color). Nuclei were counterstained by aqueous
hematoxylin (blue color). The scale bar represents 100 µm. c Asso-
ciation of BMP7 expression with score medium/high and the patho-
logical grading in CRC TMAs provided by TRISTAR technology
group. d Immunohistochemical analysis of BMP7 (red color) in
paraffin-embedded sections of colon adenomas and adenocarcinoma
(COAD). Nuclei were counterstained by aqueous hematoxylin (blue
color). The scale bar represents 100 µm. e Immunofluorescence ana-
lysis of BMP7 (green color) in CRC sphere cells and their differ-
entiated progeny SDACs. One representative of fifteen different CR-
CSC lines (CSC#1–3, 5–7, 10,11, 14–16, 18, 25, 33, and 40) is shown.
Nuclei were counterstained by Toto-3 (blue color). The scale bars
represent 20 µm. f Representative flow cytometry analysis of CD133 in
CRC sphere cells and its relative isotype-matched control (IMC)
(upper panels) performed on CSC#4, 8, and 23–26. Immuno-
fluorescence analysis of BMP7 (green color) in CD133+ and CD133−
enriched CRC sphere cell subpopulations (lower panels). Nuclei were
counterstained by Toto-3 (blue color). The scale bars represent 20 µm.
g CD44v6 expression profiles of cells as described in f (upper panels).
Expression of BMP7 (green color) in CD44v6+ and CD44v6− enri-
ched CRC sphere cell subpopulations assessed by immuno-
fluorescence analysis (lower panels). Nuclei were counterstained by
Toto-3 (blue color). The scale bars represent 20 µm. h Flow cytometry
analysis of BMP7 (green histograms) in enriched CD44v6−/CD133−,
CD44v6−/CD133+, and CD44v6+/CD133+ CRC subpopulations
performed as shown in f. Dotted line histograms indicate the
relative IMC
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reduced the colony forming capacity of CR-CSCs more
efficiently than BMP4, even in the presence of BMP
inhibitors (Fig. 3a). We have previously demonstrated that
CD44v6+ cells show upregulation of PI3K activity and
EMT-related genes [8]. Differentially expressed EMT-,
tumor metastasis- and Wnt signaling-related genes in
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CD44v6− cell compartments (Fig. 3b) were comparable
with those in CD44v6+ CRC cells treated with BMP7v
(Fig. 3c), in line with the ability of this compound to turn
CD44v6+ CSCs into CD44v6− differentiated cells. Spe-
cifically, BMP7v induced the upregulation of 7 genes and
the downregulation of other 48 genes in both CD44v6−
cells and CD44v6+ cell fractions. Of note, the gene set
enrichment analysis (GSEA) performed with the molecular
signatures database (MSigDB) revealed the activation of
programs associated with differentiation and attenuation of
EMT and metastatic biological processes (Fig. 3d, e and
Supplementary Fig. 4a, b). The most relevant down-
regulated and upregulated genes were further validated by
RT-PCR (Fig. 3f). Thus, BMP7v forces CD44v6+ CR-
CSCs towards a more differentiated phenotype.
BMP7v potentiates the effects of standard therapy
in naive and chemoresistant CR-CSCs
Following a dose-escalation delivery in vivo, we selected for
subsequent studies the 50 μg/kg dose of BMP7v, which
reduced significantly tumor growth while being well tolerated
(Supplementary Fig. 5a). Of note, BMP7v alone exerted an
antiangiogenic effect in xenograft tumors generated by the
injection of CR-CSCs. Unlike BMP4, BMP7v treatment
induced a fivefold increase in necrosis (Fig. 4a, b) and sig-
nificantly reduced the number of microvessels in CR-CSC-
based mouse avatars, as assessed by CD31 and VEGFR2
detection (Fig. 4c, d). In order to test whether BMP7v could
sensitize CR-CSCs resistant to conventional therapy, we
investigated the in vitro effect of BMP7v in combination with
a standard chemotherapy regimen.
About half of the examined CR-CSC lines showed >50%
survival after 24 h of in vitro treatment with oxa plus 5-FU
(Fig. 4e). Based on the functional characterization of che-
motherapy response, we selected four primary CR-CSC lines,
derived from metastatic liver lesions of patients progressing
after chemotherapy treatment (R1-R4), and three CR-CSC
lines (CSC#1, 2, and 7) showing different degrees of che-
moresistance. Of note, BMP7v was able to render R-CSCs
sensitive to oxa plus 5-FU in vitro treatment, the same ther-
apeutic regimen completely ineffective in vivo in the meta-
static patients from which these cells were derived (Fig. 4f).
The ability to form colonies was significantly compromised
in CR-CSCs in the presence of BMP7v in combination with
oxa plus 5-FU in vitro (Fig. 4g). This treatment affected both
the in vitro self-renewal and the in vivo tumorigenic capacity
of subcutaneously injected CR-CSCs. While tumor xenografts
generated by the injection of CSC#2 and 7 were sensitive to
the combined treatment of BMP7v and chemotherapy,
PIK3CA-mutant tumor xenografts derived from the implan-
tation of CSC#1 delayed the outgrowth showing a kinetic
trend similar to that of tumors treated with vehicle (Fig. 4h).
Immunohistochemical analysis of xenograft tumors (CSC#7)
treated with BMP7v and chemotherapy showed a reduction of
CD44v6, nuclear β-catenin, and Ki67 expressing cells, toge-
ther with a concomitant increase in CK20 positive cells (Fig. 4i).
Interestingly, xenograft tumors treated with chemotherapy
alone showed a significant increase of cells expressing
CD44v6 and nuclear β-catenin accompanied with a decrease
of Ki67 positive cells. Thus, BMP7v sensitizes both naive
and chemoresistant CR-CSCs to standard therapies.
BMP7v enhances the therapeutic response to PI3K
inhibitors and reduces the size of PIK3CA-mutant
xenograft tumors
We next investigated whether the addition of PI3K inhi-
bitors to BMP7v-based therapy could represent an
Fig. 2 BMP7v treatment promotes CR-CSC differentiation. a Phase-
contrast microscopy analysis of CD44v6+ CRC sphere cells treated
with BMP7v at the indicated time points. One representative of
CSC#1, 2, 4, 5, 7, and 23–26 is shown. The scale bar represents 20 µm.
b Percentage of CK20 positive cells in CD44v6+ CR-CSCs treated
with vehicle or BMP7v up to 21 days evaluated by immuno-
fluorescence analysis. Data are expressed as mean ± SD of experiments
performed in 15 CRC sphere cell lines (CSC#1–3, 5–7, 10,11, 14–16,
18, 25, 33, and 40). c Flow cytometry analysis of CD133/CD44v6 on
CRC sphere cells treated with vehicle or BMP7v for 14 days. Data
reported are mean ± SD of 15 CRC sphere cell lines analyzed
(CSC#1–8, 10,11, 14–16, 18, and 25). d (left panels) Immuno-
fluorescence analysis of CDX2 on CR-CSCs upon 14 days of BMP7v
treatment. One representative of CSC# 3, 9, and 21 is shown. Nuclei
were stained with Toto-3 (blue color). The scale bars represent 20 µm.
(right panel) Percentage of CDX2 positive cells in CD44v6+ CR-CSCs
treated with vehicle or BMP7v up to 14 days evaluated by immuno-
fluorescence analysis. Data are expressed as mean ± SD of experiments
performed in CSC# 3, 9, and 21. e Flow cytometry analysis of TOP-
dGFP or CD44v6 in enriched CD44v6+ sphere cells treated with
BMP7v up to 14 days. One representative experiment of CSC#1, 2, 4,
7, and 10 is shown. f Phase-contrast microscopy analysis of TOP-
dGFP CRC sphere cells grown in matrigel drops and treated with
vehicle, BMP7v or FBS for 14 days. One representative of CSC# 8, 9,
and 11 is shown. The scale bar represents 100 µm. g Immuno-
fluorescence analysis of E-cadherin, vimentin, and β-catenin (green
color) in CD44v6+ CRC cells exposed to vehicle or BMP7v for
14 days. One representative experiment performed in cells as in e is
shown. Nuclei were stained with Toto-3 (blue color). The scale bars
represent 20 µm. h Migrating CD44v6+ and CD44v6− cells treated
with vehicle or BMP7v up to 48 h. Data are shown as mean ± SD of
three independent experiments performed in five CRC sphere cell lines
(CSC#1, 5, 7, 10, and 12). i Cell viability percentage of enriched
CD44v6+ and CD44v6− cells treated with vehicle or BMP7v up to
96 h. Data are shown as mean ± SD of different experiments performed
in CSC#1, 2, 4, 7, and 10. j Cell cycle analysis in CD44v6+ CR-CSCs
exposed to vehicle or BMP7v for 72 h. The data show percentage of
cell number in sub-G0, G0/G1, S, and G2/M phases. Data are
expressed as mean ± SD of three independent experiments performed
in five different CRC sphere cell lines as in e. k Immunoblot analysis
of PARP, cleaved PARP (cPARP), Caspase-3 (Casp-3), cleaved
Caspase-3 (cCasp-3), Bcl-2, Bcl-xL in CD44v6+, and CD44v6−
enriched cells treated as in e for 72 h. β-actin was used as loading
control. One representative experiment performed in three different
CRC sphere cell lines (CSC#1, 4, and 7)
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efficacious approach in the CD44v6+ cells, particularly in
the presence of PIK3CA mutation. We first observed that
in vitro BMP7v treatment attenuated the PI3K/AKT
pathway in CD44v6+ cells, whose expression levels
became similar to those exhibited by CD44v6− compart-
ment (Fig. 5a and Supplementary Fig. 5b). Then we found
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that BMP7v combined with a PI3K inhibitor (taselisib)
was also able to revert the intrinsic chemotherapy resis-
tance of CR-CSCs in vitro (Fig. 5b). Following the inte-
gration of the dose-response and synergy score evaluation
from Bliss and ZIP algorithms, 100 ng/ml of BMP7v and
1 µM of PI3K inhibitor (taselisib) were selected for in vitro
therapeutic combination (Supplementary Fig. 5c). Thus, to
render PIK3CA-mutant CR-CSCs-derived avatars more
sensitive to the combination therapy, we decided to inhibit
the PI3K activity concomitantly. As expected, BMP7v in
combination with taselisib significantly reduced the size of
tumor xenografts generated by the injection of PIK3CA-
mutated CR-CSCs (Fig. 5c), suggesting the necessity to
simultaneously add a PI3K inhibitor in the presence of
enhanced activation of the PI3K/AKT pathway. To
determine whether the addition of BMP7v to PI3K inhi-
bitor, taselisib could also induce regression of the disease,
metastatic mouse avatars generated by the injection of
PIK3CA-mutated CR-CSCs into NOD-SCID mice spleen,
were treated 4 weeks after the splenectomy once the
metastatic lesions were detectable. The combination of
PI3K and BMP7v significantly lessened the size of meta-
static lesions of PIK3CA-mutated CR-CSCs, even 4 weeks
after treatment suspension (Fig. 5d-f). The majority of
CD44v6+ cells found in the liver and lung metastases of
mice treated with the PI3Ki-BMP7v combination therapy
underwent cell death, confirming the potential clinical
application of this therapeutic approach in patients with
metastatic CRC (Fig. 5g, h). Altogether, these findings
suggest that BMP7v can turn CD44v6+ cells into a therapy
sensitive CD44v6− differentiated phenotype. Although
PIK3CA-mutated CR-CSCs are less sensitive to the pro-
differentiation activity of BMP7 signaling, the addition of
a PI3K inhibitor restores their sensitivity in established
tumors (Fig. 6a).
Discussion
We previously demonstrated that CD44v6 is a functional
receptor that identifies migrating CSCs able to develop
CRC metastasis [8]. Here, we show that CD44v6 enriched
CR-CSCs lack the expression of BMP7, which is con-
versely confined within the differentiated counterpart
(CD44v6− cells). The heterogeneous expression of BMP7
within the CD44v6− compartment is likely due to the
presence of progenitor cells (CD44v6−/CD133+ cells)
endowed with residual β-catenin activation, which renders
these cells reprogrammable by the microenvironmental
cytokines [8]. Here, we show that BMP7 expression
represents an early event in CRC as confirmed by its
presence in colon adenoma and adenocarcinoma. More-
over, its expression inversely correlated with the patho-
logical grading of CRCs, again supporting the association
between this morphogen and differentiated tumor. In
accordance with the reported effects in glioma stem cells
[41], BMP7v induce the expression of differentiation
markers in CR-CSCs, which gradually reduce their
β-catenin activity and CD44v6 expression. We previously
reported that BMP4 promotes differentiation and affects
the self-renewal activity of CR-CSCs [24]. Through a
SMAD1/4-mediated epigenetic mechanism, BMP4 leads to
the recruitment of histone deacetylase HDAC1 and con-
sequent transcriptional suppression of stemness genes
[42]. Accordingly, targeting the Wnt pathway by BMP7v
curtails the clonogenic activity of CD44v6+ CRC cells and
leads to their terminal differentiation, as highlighted by the
presence of PARP activation and downregulation of the
antiapoptotic proteins Bcl-2 and Bcl-xL. The similar trend
of cell viability in both CD44v6+ and CD44v6− popula-
tions is likely due to the presence, in the CD44v6− frac-
tion, of progenitor cells that are affected by the BMP7v
treatment. Tumor microenvironment reprograms cancer
cells towards an EMT process leading them to acquire a
more pronounced self-renewal and migratory phenotype
[8, 43]. We have shown that cytokines released by cancer-
associated fibroblasts are able to dedifferentiate CD44v6−
cells into CD44v6+ metastatic CR-CSCs, with the induc-
tion of a number of EMT genes [8]. BMP7v drives CR-
CSCs to behave similarly to the differentiated CD44v6−
cells by downregulating the majority of EMT-related
genes, which are needed by CD44v6+ cells to retain an
Fig. 3 BMP7v hampers the self-renewal and recapitulates a CD44v6−-like
cell subpopulation profile. a Colony forming efficiency percentage of
CD44v6+ CR-CSCs treated for 14 days with vehicle, gremlin or
noggin alone or in combination with BMP4 or BMP7v. Data are
reported as mean ± SD of five different CRC sphere cell lines analyzed
(CSC#1, 2, 4, 7, and 10). Representative soft-agar analysis is shown in
the lower part of graph. b Heat map of EMT-, tumor metastasis-, and
Wnt pathway-related genes (2−ΔΔCt expression values) in spheres,
CD44v6− and CD44v6+ cells. Data are presented as normalized
expression values of three different CRC sphere cell lines (CSC#4, 8,
and 18). c Log fold change (logFC) values of differentially expressed
related genes in enriched CD44v6+ cells treated with BMP7v for
3 days. Data are presented as the average of normalized mRNA
expression levels of four different CR-CSC lines (CSC#1, 3, 5, and 7).
Dotted lines represent −1 and 1 logFC values. P value indicates dif-
ference between normalized mRNA expression levels of untreated vs
BMP7v treated samples. d Venn diagram showing upregulated (red)
and e downregulated (green) genes in CD44v6− and BMP7v treated
cells. (Lower panels) Top ten significantly enriched gene sets (FDR
q value ≤ 0.05), selected by using Hallmark, KEGG, and GO, related to
the indicated 7 up- and 48 down-regulated genes common in CD44v6−
cells and CD44v6+ cells treated with BMP7v. P values related to each
enriched gene set are indicated. f Fold change values of the differen-
tially upregulated (red) and downregulated (green) genes further
validated by RT-PCR in CR-CSCs upon treatment with BMP7v for
72 h. Data are expressed as mean ± SD of experiments performed in
CSC# 1, 3, 9, and 21
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aggressive phenotype. We previously demonstrated that
BMP4 induces PTEN upregulation and inhibition of PI3K/
AKT [24], which sustains the stem-like cell properties of
CD44v6+ CR-CSCs [8]. BMP7v displays a similar inhi-
bition on the PI3K/AKT pathway. Here, we have shown
that even though PTEN increased moderately upon
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BMP7v treatment, PI3K protein expression, and AKT
activation levels decreased significantly in CD44v6+ cells,
which differentiate and revert to CD44v6−/PI3Klow cells.
This mechanism is in line with the observation that the
natural compound resveratrol inhibits the PI3K pathway
by upregulating the BMP7 in human colon cancer cells
[44]. The induction of differentiation may represent an
alternative therapeutic approach to render CSCs sensitive
to standard therapies [24, 45]. Differentiation therapy is
currently in phase 2 clinical trial for the cure of acute
promyelocytic leukemia [46]. The expression of anti-
apoptotic genes and the upregulation of survival factors
contribute to CSC resistance to conventional anticancer
therapies [32].
BMP7v reduces the expression levels of anti-apoptotic
proteins and makes PIK3CA wt CRC avatars sensitive to
standard chemotherapy. In addition, BMP7v enhances the
therapeutic response even against CR-CSCs purified from
metastatic lesions of patients who underwent chemotherapy.
About 10–30% of CRCs exhibit PI3K activation sustained by
PIK3CA mutations, which contribute to confer resistance to
standard therapies and targeted agents [47]. PIK3CA-mutated
tumor xenografts display resistance to the combination of
BMP7v and chemotherapy. This is not surprising because it is
likely that the increased β-catenin activation promoted by the
constitutive activation of PI3K counteracts the inhibitory
activity on the Wnt pathway induced by BMP signaling.
PI3K is a target for pharmacological drug design and
therapeutic intervention in many cancers, including CRC [48].
Nowadays, although PI3K inhibitors have a limited effect as
single agents in CRC, several clinical trials are exploring the
efficacy of these inhibitors in different combinatorial treat-
ments [47, 49]. Here we showed that BMP7v is able to
sensitize chemoresistant CR-CSCs to PI3K inhibitors in vitro
regardless their MSI and CMS profiles. Addition of a PI3K
inhibitor to the combination of BMP7v and chemotherapy-
induced tumor regression of PIK3CA-mutant tumor xeno-
graft, further supporting the potential clinical application of
this combination therapy. In line with our previous findings,
PI3K inhibitors alone selectively target disseminating CR-
CSCs [8], whereas in combination with BMP7v treatment
induce disease regression by reducing the size of both primary
tumors and established CRC liver metastasis.
In conclusion, we have shown that BMP7v exerts a potent
antitumor activity through the induction of differentiation of
PIK3CA wt CR-CSCs. Although the presence of PIK3CA
mutation reduces the therapeutic activity of BMP7v, we
provide evidence that the addition of PI3K inhibitors may be
sufficient to restore CR-CSC sensitivity to BMP7v. Unlike
BMP4, BMP7v exerts a significant antiangiogenic effect and
can be administered systemically, due to its solubility and
prolonged half-life, which also facilitate its combination with
standard chemotherapy or targeted agents. Further studies are
needed to investigate the minimal residual disease upon the
combination therapy based on BMP7v and PI3K inhibitor.
Because the efficacy of targeted therapy is limited by the
presence of intratumor heterogeneity, this prodifferentiation
approach coupled with such a considerable antiangiogenic
activity may contribute to overcome the hurdles of dynamic
tumor changes. Thus, BMP7v-based combination therapies
may represent potential novel treatment options for CRC.
Materials and methods
Isolation and treatment of CR-CSCs
Human CRC tissues were obtained from 40 patients at the
time of resection, in accordance with the ethical standards of
Fig. 4 BMP7v exerts antiangiogenic effects and sensitizes chemore-
sistant CSCs to standard therapy. a Azan-Mallory staining on paraffin-
embedded sections of xenografts derived from the injection of CRC
sphere cells and treated for 4 weeks (6–9 weeks) with PBS (vehicle) or
BMP7v. Data are representative of three independent experiments
using different CRC sphere cell lines (CSC#2, 7, and 18). b Percentage
of necrosis evaluated on paraffin-embedded sections of xenografts
treated as in a. Data are shown as mean ± SD of three independent
experiments. c Immunohistochemical analysis of CD31 and VEGFR2
(red staining) on paraffin-embedded sections of xenografts generated
by the injection of CRC sphere cell lines and treated with PBS
(vehicle), BMP4, or BMP7v. Green arrowheads indicate microvessels
expressing CD31 or VEGFR2. Images are representative of three
independent experiments using cells as in a. Nuclei were revealed by
hematoxylin staining (blue). The scale bar represents 20 µm. d Number
of microvessels positive for CD31 (left panel) and VEGFR2 (right
panel) expression, evaluated on paraffin-embedded sections of xeno-
grafts treated as in c. Data are shown as mean ± SD of cells. MVD=
microvessel density. e Fold change of viable cells in 35 CR-CSC lines
treated with oxaliplatin/5-FU for 24 h. Dotted line indicates the
threshold between chemoresistant (red) and sensitive CR-CSCs
(green). f Cell viability percentage in chemoresistant CR-CSCs (R1-
R4) pretreated with BMP7 for 3 days and with oxaliplatin/5-FU (oxa/
5-FU) for additional 24 h as indicated. Data are shown as mean ± SD
of three different experiments performed in the indicated R-CSCs.
g Colony forming efficiency of CR-CSCs treated as in f and evaluated
at 21 days. Representative soft-agar analyses are reported in the lower
part of the graph. Bars show the mean ± SD of seven different CRC
sphere cell lines (CSC#1–3, 5, 7, 10, and 18). h Tumor size of sub-
cutaneous growth of the indicated CR-CSCs. Mice were treated for
4 weeks (6–9 weeks) with vehicle, oxaliplatin/5-FU (oxa/5-FU) and
BMP7v alone or in combination. Error bars show the mean ± SD of
tumor size measured in six mice/group. Black arrowheads indicate
days of treatment. i Immunohistochemical analysis of CD44v6,
β-catenin, Ki67, and CK20 (red color) in paraffin-embedded sections
of CSC#7 xenografts treated as in h. Nuclei were counterstained by
aqueous hematoxylin (blue color). The scale bar represents 20 µm (left
panels). Percentage of CD44v6, β-catenin, Ki67, and CK20 positive
cells in paraffin-embedded sections of tumor xenografts treated with
vehicle (V), BMP7v (B), oxaliplatin/5-FU (O/F), alone or in combi-
nation (B/O/F) for 72 h. Error bars are mean ± SD of positive cell
counts in three serial embedded-paraffin sections of six tumor xeno-
grafts per group derived from the injection of three different CRC
sphere cells (CSC#1, 2, and 7) (right panels)
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the Institutional Committee on Human Experimentation
(authorization CE9/2015, Policlinico Paolo Giaccone,
Palermo) after informed consent. Peritumoral mucosa was
recovered from the uninvolved surrounding tumor tissue.
Clinical data of CRC patients from which CRC sphere cell
lines were derived are reported in Supplementary Table 1.
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CRC sphere cells were isolated and propagated as previously
described [8, 32]. Briefly, specimens were digested in
DMEM medium supplemented with 10 µg/ml of hyalur-
onidase (Sigma) and 0.6 mg/ml of collagenase (Gibco) for
1 h at 37 °C, resuspended in serum-free stem cell medium
comprising EGF (Peprotech) and FGF2 (Peprotech) and
cultured in ultra-low adhesion flasks. To generate SDACs,
CR-CSCs were dissociated and then cultured in DMEM-high
glucose supplemented with 10% FBS in adherent conditions
up to 21 days [24]. Gradual morphological differentiation
was determined by counting of cells in adherent conditions
normalized with the number of CR-CSCs in suspension. To
evaluate differentiation of CRC organoids, CR-CSCs were
dissolved in a 1:10 stem cell medium/Matrigel solution,
placed in a 24-well plate as a single drop covered by medium
and monitored twice a week up to 21 days.
Authentication of CRC sphere cell lines was assessed by
short tandem repeat (STR) DNA profiling (GlobalFiler™
STR kit, Applied Biosystem) using the ABIPRISM 3130
genetic analyzer (Applied Biosystem) as recommended by
the manufacturer’s instructions. STR profiles of CRC sphere
cells were matched with their relative patient-derived tumors.
Primary cultures enriched in CSCs derived from chemore-
sistant metastatic liver lesions were obtained from patients
undergoing hepatectomy with curative intent at the Uni-
versity Polyclinic A. Gemelli, Rome. Cell cultures were
monitored for the presence of mycoplasma. CRC sphere cells
and their enriched CD44v6+ and CD44v6− fractions were
treated with BMP7v (100 ng/ml produced by Eli Lilly as
previously described) [30], gremlin (1 µg/ml, R&D Systems),
noggin (100 ng/ml, R&D Systems), BMP4 (100 ng/ml, R&D
Systems), oxa (10 µM, Selleckchem), 5-FU (10 µM, Sell-
eckchem), and taselisib (PI3Ki, 1 µM GDC-0032, Chemie-
tek). Oxa was added to cell culture media 2 h before 5-FU
treatment. All the compounds above described were added to
cell culture media every 48 h. BMP7v dose was determined
by the evaluation of colony forming efficiency in presence of
different concentration of BMP inhibitors (gremlin and
noggin), when in combination with PI3K inhibitor (taselisib)
its effective dose was selected on the basis of CR-CSC via-
bility. These experiments were conducted in SynergyFinder,
including Bliss and ZIP, to calculate dose-response inhibition
matrix and synergy scores [50].
Fig. 5 BMP7v in combination with PI3K inhibitor hampers tumor
growth and reduces the metastatic lesion size. a Immunoblot analysis
of PI3K, pAKT, AKT, PTEN, pJNK, JNK, pERK, ERK, and p21 in
CD44v6+ and CD44v6− cells treated with vehicle or BMP7v for
3 days. β-actin was used as loading control. One representative of three
independent experiments (CSC#1, 4, and 7) is shown. b Cell viability
percentage in R-CSCs treated with vehicle, BMP7v, PI3K inhibitor
(PI3Ki), or BMP7v in combination with PI3K inhibitor (BMP7v+
PI3Ki) up to 72 h. Data are shown as mean ± SD of three different
experiments performed with the indicated R-CSCs. c Tumor size of
subcutaneous outgrowth of PIK3CA-mutated xenografts. Mice were
treated with vehicle, PI3K inhibitor (PI3Ki), oxaliplatin/5-FU (oxa/5-
FU), BMP7v in combination with PI3K inhibitor (BMP7v+ PI3Ki) or
BMP7 in combination with PI3K inhibitor and oxaliplatin/5-FU
(BMP7v+ PI3Ki+ oxa/5-FU). Data are shown as mean ± SD of
tumor size of six mice/group using CSC#1, 18, and 25. Red arrows
indicate the start and the end (from 6 to 9 weeks) of treatments.
d Kinetics of metastasis formation detected by in vivo imaging ana-
lysis at the indicated time following spleen injection of CSC#1, 18,
and 25 treated with vehicle, BMP7v, PI3K inhibitor (PI3Ki), or
BMP7v in combination with PI3K inhibitor (BMP7v+ PI3Ki) for
4 weeks. Black arrows indicate the start and end of treatments (from
4 to 7 weeks). Data are expressed as mean ± SD of six mice analyzed.
e In vivo whole-body imaging analysis of mice treated as in d and
analyzed at the indicated time points after splenectomy. f Photons
count of all metastatic sites (liver, lung, and intestine) in mice treated
as in d. Error bars are reported as mean ± SD of the xenografts ana-
lyzed as in d (upper panel). Representative in vivo imaging analysis of
metastatic foci in the liver, lung, and intestine of mice treated as
indicated (lower panels). g Immunofluorescence analysis of CD44v6
(red color) and TUNEL (green color) in paraffin-embedded sections of
lung metastasis generated by the injection of CSC#25 in mice treated
with vehicle or BMP7v+ PI3K inhibitor (BMP7v+ PI3Ki). White
arrowheads indicate CD44v6+/Tunel+ CRC cells. Nuclei were coun-
terstained with Toto-3 (blue color). Positive control was performed
treating cells with DNase. The scale bars represent 20 µm. h Percen-
tage of CD44v6+/Tunel+ cells of lung metastasis treated with vehicle
or BMP7v+ PI3K inhibitor (BMP7v+ PI3Ki). Data are mean ± SD of
xenografts derived from injection of three different cell lines (CSC#1,
18, and 25)
Fig. 6 Schematic model of BMP7v effects in primary and metastatic
CRC. a In primary tumor the colon cancer crypt organization, which is
physiologically maintained by BMPs/BMP inhibitor balance, is dis-
rupted. The administration of BMP7v selectively counteracts the
expansion of the CSC compartment by reducing CD44v6 expression.
Moreover, BMP inhibitors (noggin, gremlin, and others), produced by
myofibroblasts, are not able to inhibit BMP7v activity on promoting
the differentiation of CSCs (upper panel). In metastatic tumor, BMP7v
in combination with PI3K inhibitors reduces the number of CD44v6+
cells and hampers the tumor metastatic growth (bottom panel). CSC
cancer stem cell, DCC differentiated cancer cell, DC differentiated cell
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Immunohistochemistry and Immunofluorescence
Immunohistochemistry analysis was performed on 5-μm-
thick paraffin-embedded sections of CRC tissues or CRC
sphere cell-derived tumor xenografts. For intracellular
epitope detection, tissue sections were permeabilized in
ice-cold 0.1% TritonX-100 in PBS for 10 min. Tissue
samples were exposed overnight at 4 °C to specific anti-
bodies for BMP7 (MAB3541, mouse, IgG2b, R&D sys-
tem), E-cadherin (#3195, rabbit, IgG, CST), CD31
(M0823, clone JC70A, mouse IgG1k, Dako), VEGFR2
(AF357, goat, IgG, R&D System), CD44v6 (BBA13,
clone 2F10, mouse, IgG1, R&D system), β-catenin (sc-
7199, rabbit, IgG, Santa Cruz Biotechnology), Ki67
(M7240, mouse, IgG1, DakoCytomation), and CK20
(NCL-L-CK20, mouse, IgG2k, Novocastra Leica). Pri-
mary antibodies were revealed by biotin-streptavidin
peroxidase LSAB 2 Kit (Dako). Stainings were detected
by using 3-amino-9- ethylcarbazole chromogen. Nuclei
were counterstained with aqueous hematoxylin (Sigma).
For Azan-Mallory, tissues were stained with azocarmine
G (Sigma) and 5% of phosphoric acid. Then, sections were
stained with a Mallory mix solution (Sigma). Staining was
analyzed by using Imaging Analyzer Software.
Immunofluorescence staining was performed on
paraffin-embedded sections, cells cytospun or cultured on
coverslips. Cells were fixed in 2% paraformaldehyde for
20 min at 37 °C. Intracellular epitope detection was per-
formed in cells permeabilized in 0.1% TritonX-100 in PBS
for 10 min. Following blocking with 3% bovine serum
albumin (BSA) for 30 min, cells were exposed overnight at
4 °C to BMP7 (MAB3541, mouse, IgG2b, R&D system),
LGR5 (GPR49, rabbit, IgG, Abgent), CDX2 (MAB3665,
mouse, IgG1, R&D Systems), CK20 (NCL-L-CK20,
mouse, IgG2k, Novocastra Leica), E-cadherin (#3195,
rabbit, IgG, CST), vimentin (#5741, rabbit, IgG, CST),
β-catenin (MAB1329, mouse, IgG2b, R&D Systems),
CD44v6 (BBA13, clone 2F10, mouse, IgG1, R&D sys-
tem), BMPR1A (MAB2406, mouse, IgG2b, R&D Sys-
tems), BMPR1B (MAB505, mouse, IgG2a, R&D Systems)
and, BMPR2 (MAB811, mouse, IgG2b, R&D Systems)
antibodies or isotype-matched controls (IMCs). Primary
antibodies were revealed using Alexa Fluor 488 or
Rhodamine-conjugated anti-mouse or anti-rabbit second-
ary antibodies (Invitrogen) in the presence of RNase
(40 μg/ml, Sigma). Nuclei were counterstained using Toto-
3 iodide (Molecular Probes).
Cell quantitation was performed by ImageJ Software
analysis. Tunel assay was performed by using In Situ Cell
Death Detection, AP Kit(Roche Diagnostics GmbH). DNA
strand breaks were detected by 5-bromo-4-chloro-3-indolyl-
phosphate (, Dako) substrate. DNase was used to perform
the positive control.
TMAs were provided by TriStar Technology group (Tri),
LLC, 9700 Great Seneca Highway, Rockville, MD 20850.
Flow cytometry and cell cycle analysis
CD133 and CD44v6 positive and negative subpopulations
were obtained using FACS cell sorter (BD). Cells were
stained for 1 h at 4 °C with CD133-PE (130-090-851,
293C3, mouse IgG2b, Miltenyi), CD44v6-APC
(FAB3660A, clone 2F10, mouse, IgG1, R&D systems) or
corresponding IMCs IgG2b-PE (#130-092-215, mouse,
Miltenyi) or IgG1-APC (#IC002A, mouse, R&D systems).
Before sorting, cells were resuspended in PBS supple-
mented with 2% BSA and 2 mM EDTA, and strained
through a 70 µm mesh to avoid cell hindrance. Dead cells
were excluded with 7-AAD (BD). Quality of postsorting
was verified by flow cytometry using specific antibodies
against CD133 (170-070-702, CD133/1-APC, AC133,
mouse IgG1k, Miltenyi) or CD44v6 (#MA5-16966,
CD44v6-FITC, VFF-7, mouse IgG1, Thermo Scientific).
Cells were then washed twice in PBS, permeabilized with
fixation/permeabilization solution (Cytofix/Cytoperm, BD)
following the manufacturer’s instructions and stained with
BMP7-FITC (FCMAB135F, 2A10, mouse IgG1k, Merck)
or its IMC IgG1k (#F6397, mouse, Sigma-Aldrich). For
flow cytometry analysis of CD133 and CD44v6, PE-
(293C3) or APC-conjugated (2F10) clone were used,
respectively. Cell cycle analysis was performed by quanti-
fication of DNA content on dissociated cells. Cells were
incubated overnight at 4 °C in a buffer containing 50 μg/ml
propidium iodide (Sigma-Aldrich), 0.1% sodium citrate
(Sigma-Aldrich), 0.1% TritonX-100 and 10 μg/ml RNAse
(Sigma-Aldrich). All data were analyzed using FlowJo
software (Tree Star). The percentage of CD44v6+ cells has
been assessed in all the 35 CRC sphere cell lines and
indicated as low (<30%), medium (30–70%), and high
(>70%) in Supplementary Table 2.
Lentiviral particles generation and CR-CSC
transduction
To generate lentiviral particles, packaging cell line HEK-
293T were transfected with second-generation packaging
plasmids (PSPAX2 and pMD2.G plasmids Addgene) in
association with p-TWEEN LUC or TOP-dGFP (Addgene #
35489) lentiviral vectors. Transfection was performed using
X-tremeGENE HP DNA Transfection Reagent (Roche).
Lentiviral supernatants were collected and concentrated
with the Lenti-X Concentrator reagent (Clontech). 1 × 105
CRC sphere cells were transduced with concentrated viral
supernatants for 24 h using 8 μg/ml polybrene. Wnt path-
way activity was monitored by flow cytometry analysis on
the basis of the TOP-dGFP expression levels.
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Cell viability, clonogenic, and invasion assay
The cell viability assay was performed using the CellTi-
ter96® Aqueous One Solution Cell Proliferation Assay Kit
(Promega) according to the manufacturer’s instructions
and examined with GDV programmable MPT reader (DV
990 BV6). For invasion assay, 2 × 103 dissociated CR-
CSCs were plated into 8 µm pore size matrigel (BD)-
coated transwell and treated with vehicle or BMP7v up to
48 h. Supernatant of NIH-3T3 cells cultured in serum-free
medium was used as chemoattractant in the lower part of
the transwell system. Migrating cells were examined and
counted using an optical microscope. For clonogenicity,
CR-CSCs were plated at a clonal density on Agarose Sea
Plague Agar (Invitrogen) and maintained up to 21 days.
Colonies were stained with 0.01% Crystal Violet, eval-
uated based on their size (small 30–60 µm, medium
60–90 µm, and large >90 µm) and counted using ImageJ
software.
Western blot analysis
Cell pellets were resuspended in ice-cold lysis buffer (50 mM
Tris-HCL pH 8, 150mM NaCl, 0.5% sodium deoxycholate,
0.1% SDS, 1% NP40, 1 mM EDTA) supplemented with a
mix of protease and phosphatase inhibitors (Thermo Fisher
Scientific). Equal amount of protein extracts was resolved on
SDS-PAGE gels and blotted on nitrocellulose membranes.
Membranes were exposed overnight at 4 °C to PARP
(#9524, rabbit, IgG, CST), Caspase-3 (#9662, rabbit, IgG,
CST), cleaved Caspase-3 (Asp175) (#9661, rabbit, IgG,
CST), Bcl-2 (sc-7382, mouse, IgG, Santa Cruz), Bcl-xL (sc-
8392, mouse, IgG, Santa Cruz), PI3K (p110α) (#4249,
C73F8, rabbit, IgG, CST), phospho-AKT (Ser473 XP)
(#4060, D9E, rabbit, IgG, CST), AKT (#9272, rabbit, IgG,
CST), PTEN (#9559, 138G6, rabbit, IgG, CST), phospho-
JNK (Thr183/Tyr185) (#4668, 81E11, rabbit, IgG, CST),
JNK (#9258, 56G8, rabbit, IgG, CST), phospho-ERK
(sc-7383, E-4, mouse, IgG2a, Santa Cruz), ERK (sc-94,
rabbit, IgG, Santa Cruz), p21 (#2946, DCS60, mouse IgG2a,
CST), and β-actin (#3700, 8H10D10, mouse IgG2b, CST).
Primary antibodies were detected using specific secondary
HRP-conjugated antibodies (Thermo Fisher Scientific)
and chemiluminescence signals were revealed using Amer-
sham imager 600 (GE Healthcare). Protein expression levels
were measured by densitometry analysis using ImageJ
software.
Mutation analysis and MSI profile
Total DNA was purified from CR-CSCs using the Blood and
Tissue Kit (QIAGEN). The mutational status of KRAS,
BRAF, PIK3CA, and SMAD4 genes was evaluated by the
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied





R-TAATGTGCCAACTACCAATG) and SMAD4R361 (F-TG
TGGAGTGCAAGTGAAAGC, R-TCAATGGCTTCTGTC
CTGTG). Codon Code Aligner Software was used for
sequence assembly and alignment. Assessment of MSI status
of CR-CSCs was carried out using the GeneQuality CC-MSI
kit (Analitica Advanced Biomedicine). Purified total DNA
was subjected to a multiplex microsatellite PCR including
mononucleotide repeats (BAT25, BAT26, BAT40, NR21,
NR24, and TGFβRII) and dinucleotide repeats (D2S123,
D17S250, D5S346, and D18S58). MSI analysis was carried
out using GeneMapper 5.0 Software (Applied Biosystems).
Samples were classified as MSI-high (four or more markers
instable), MSI-low (1–3 markers instable), or MSS (micro-
satellite stable). Mutation and MSI profiles of CR-CSCs
were performed on a Genetic Analyzer ABIPRISM 3130
(Applied Biosystems). COSMIC-reported mutations of
KRAS, BRAF, PIK3CA, and SMAD4 in the 35 CRC sphere
cell lines used and their MSI profiles are indicated in Sup-
plementary Table 2.
RNA isolation and Real-time PCR
Total RNA was obtained using the RNeasy Plus Mini Kit
(Qiagen GmbH) according to the manufacturer’s instruc-
tions. The yield of the extracted RNA was determined by
Nanodrop ND-1000 (Nanodrop, Wilmington, DE). One
microgram of total RNA was retro-transcribed using the
High-Capacity cDNA Archive Kit (Applied Biosystems)
following the standard protocol. Quantitative real-time PCR
analysis was performed in SYBR Green PCR master mix






ATCTCCTCGTGGT), TGFβ1 (F- CTCGCCCTGTACA
ACAGCA, R-GGTTTCCACCATTAGCACGC), TGFβ2
(ACAGACCCTACTTCAGAATTGTT, R-TGGGTTCTG
CAAACGAAAGA) CDH2 (F- GGAGAACCCCATTGA
CATTGT, R-TGTTCCAGGCTTTGATCCCT), MMP2
(TGGTGGGAACTCAGAAGGTG, R-CCACATCTTT
CCGTCACTGC), MMP9 (F- ACTACTGTGCCTTT
GAGTCC, R-CCAGTACTTCCCATCCTTGA), or
GAPDH (F-GCTTCGCTCTCTGCTCCTCCTGT, R-
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TACGACCAAATCCGTTGACTCCG). Relative mRNA
expression levels were normalized with the endogenous
control (GAPDH) and calculated using the comparative Ct
method 2−ΔΔCt. mRNA expression levels of EMT-, tumor
metastasis-, and Wnt pathway-related genes were detected
by RT2 profiler PCR array (PAHS-090, Qiagen) according
to manufacturers’ instructions. Data were analyzed using
the R version 3.5.0 and plotted by the pheatmap version
1.0.10 and VennDiagram 1.6.20, gtools 3.8.1, and ggplot2
3.0.0. GSEA was performed by selecting the Kyoto Ency-
clopedia of Genes and Genomes, Gene Ontology and
Hallmarks within MSigDB version 6.2. Gene sets with a
False Discovery Rate q value ≤ 0.05 were considered sig-
nificantly enriched. CMS1–4 profile of CR-CSCs was based
on the evaluation of RNA-seq data on matched specimens
derived from primary lesions of CRC patients as reported in
Linnekamp et al. [51]. Correlation analysis data were
obtained using the “R2: Genomics Analysis and Visuali-
zation Platform” (http://r2.amc.nl http://r2platform.com) in
CRC samples from the Expression Project for Oncology
(GEO accession number GSE2109).
Animals and tumor models
Dissociated CRC sphere cells (5 × 105) were injected sub-
cutaneously into the flank of 5–6-week-old male NOD-SCID
mice (Charles River), in a total volume of 100 µl of serum-
free medium mixed with matrigel (BD) in a ratio of 1:1. The
Replacement, Reduction, and Refinement (3Rs) principles
were used to estimate the lowest sample size (six mice per
group).
Mice were treated for four weeks with PBS (vehicle) or
BMP7v (50 μg/kg, 3 days/week) alone or in combination
with oxa (0.25 mg/kg, once a week) and 5-FU (15 mg/kg,
2 days/week) by i.p. injection, and with taselisib (5 mg/kg,
once daily) by oral gavage. Treatment with BMP4 was
performed by intratumoral injection of 100 BMP4-coated
beads once a week for 6 weeks. Heparin acrylic beads
(Sigma) were incubated with BMP4 (0.65 μg/μl) for 1 h at
37 °C and washed twice in PBS.
Tumor size was calculated according to the formula: (π/
6) × (smaller diameter)2 × larger diameter.
For in vivo migration experiments, 3 × 105 luciferase
(LUC)-transduced CD44v6+ CR-CSCs were resuspended in
PBS and injected into the spleen of NOD/SCID mice. Fol-
lowing i.p. administration of D-luciferin (150mg/kg, Pro-
mega), the bioluminescence signal of migrating cells was
measured before and 30min after the cell injection and
immediately after splenectomy up to 12 weeks (every
4 weeks) by using Photon IMAGER instrument (Biospace).
No randomization procedure was used. Investigators were not
blinded during analysis.
Statistical analysis
The sample size was chosen to reach a power of 0.9, 0.05
error probability and a large effect size (>0.5) for our groups
of treatments. Data were presented as mean ± standard
deviation. Statistical significance was estimated by Analysis
of Variance (one way or two ways) with Bonferroni post
test, or by unpaired T test. Results were referred to statis-
tically significant as P < 0.05. * indicates P < 0.05, **
indicate P < 0.01, and *** indicate P < 0.001.
Study approval
This study was performed in accordance with the ethical
standards of the Institutional Committee on Human
Experimentation (authorization CE9/2015, Policlinico
Paolo Giaccone, Palermo). All animal experiments were
approved by the Institutional Italian Guidelines for Animal
Welfare of the University of Palermo (D.L. n° 26 March 4,
2014, Authorization #154/2017-PR; Protocol 2B952.5).
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